Article
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Blood - 9 Jul 2020
Malcovati Luca, Stevenson Kristen, Papaemmanuil Elli, Neuberg Donna, Bejar Rafael, Boultwood Jacqueline, Bowen David T, Campbell Peter J, Ebert Benjamin L, Fenaux Pierre, Haferlach Torsten, Heuser Michael, Jansen Joop H, Komrokji Rami S, Maciejewski Jaroslaw P, Walter Matthew J, Fontenay Michaela, Garcia-Manero Guillermo, Graubert Timothy A, Karsan Aly, Meggendorfer Manja, Pellagatti Andrea, Sallman David A, Savona Michael R, Sekeres Mikkael A, Steensma David P, Tauro Sudhir, Thol Felicitas, Vyas Paresh, Van de Loosdrecht Arjan A, Haase Detlef, Tüchler Heinz, Greenberg Peter L, Ogawa Seishi, Hellstrom-Lindberg Eva, Cazzola Mario
Abstract excerpt
The 2016 revision of the World Health Organization classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of morphology and molecular genetics. Notwithstanding, the myelodysplastic syndrome (MDS) with isolated del(5q) remains so far the only MDS subtype defined by a genetic abnormality. Approximately half of MDS patients carry somatic mutations in spliceosome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.